Syros Pharmaceuticals, Inc. operates as a biopharmaceutical firm primarily focused on discovering and developing novel therapeutic solutions for various cancers and monogenic (single-gene) diseases. A key strategic aim for the company involves cultivating a robust pipeline of medicines that modulate gene expression. Its leading investigational drug candidates include: Tamibarotene: A selective retinoic acid receptor alpha agonist, currently undergoing Phase III clinical trials for a genetically defined subset of patients with myelodysplastic syndrome, and in Phase II trials for individuals suffering from acute myeloid leukemia.
| Date | Est. | Actual | |
|---|---|---|---|
| Mar 26, 2025 | -$0.70 | -$1.19 | Miss |
| Oct 31, 2024 | -$0.76 | -$0.16 | Beat |
| Jul 31, 2024 | -$0.79 | -$0.70 | Beat |
| May 14, 2024 | -$0.89 | -$0.10 | Beat |
| Mar 27, 2024 | -$1.14 | -$2.18 | Miss |
| Nov 14, 2023 | -$1.12 | -$1.35 | Miss |